Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of canagliflozin monohydrate versus hemihydrate in healthy adults under fasted conditions
NL-OMON42409Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Bioequivalence. Started Sep 2015; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON42409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42409.